Ritter Daniher Financial Advisory LLC DE Purchases New Shares in Johnson & Johnson (NYSE:JNJ)

Ritter Daniher Financial Advisory LLC DE acquired a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 828 shares of the company’s stock, valued at approximately $147,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. AXS Investments LLC grew its holdings in Johnson & Johnson by 129.0% during the 2nd quarter. AXS Investments LLC now owns 8,205 shares of the company’s stock worth $1,456,000 after acquiring an additional 4,622 shares in the last quarter. Pinnacle Holdings LLC grew its holdings in Johnson & Johnson by 0.9% during the 2nd quarter. Pinnacle Holdings LLC now owns 15,678 shares of the company’s stock worth $2,783,000 after acquiring an additional 141 shares in the last quarter. KerberRose Wealth Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth $420,000. Corepath Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 43.9% in the 2nd quarter. Corepath Wealth Partners LLC now owns 2,629 shares of the company’s stock valued at $462,000 after buying an additional 802 shares during the period. Finally, Wagner Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 18.0% in the 2nd quarter. Wagner Wealth Management LLC now owns 2,553 shares of the company’s stock valued at $453,000 after buying an additional 389 shares during the period. 68.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JNJ. Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Citigroup cut their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Finally, Bank of America cut their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $177.01 on Thursday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a market capitalization of $462.79 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57. The firm’s 50-day moving average is $168.35 and its two-hundred day moving average is $171.28. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same period in the previous year, the firm earned $2.60 EPS. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson declared that its board has authorized a stock repurchase program on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. Insiders have sold 212,646 shares of company stock valued at $36,791,022 in the last quarter. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.